- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00791063
18F ML-10 for Early Detection of Response of Brain Metastases to WBRT
An Open-Label Study to Evaluate 18F ML-10 as a PET Imaging Radiotracer for Early Detection of Response of Brain Metastases to Whole Brain Radiation Therapy (WBRT)
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Early assessment of the efficacy of anti-cancer therapy is highly desirable and an unmet need in clinical oncology. Currently, treatment efficacy is mostly measured by following tumor size by anatomical imaging (CT scan or MRI). However, changes in tumor size may be observed only after several weeks to several months after completion of treatment. Meanwhile, in cases where there is no response, the patient is unnecessarily exposed to treatment's side effects, and precious time may be lost before the initiation of an alternative, potentially more beneficial line of therapy. Therefore, there is an urgent and serious need for better tools for monitoring of tumor response to anti-cancer treatments.
To address this need, [18F]-ML-10, a novel small molecular-weight probe (MW 205) was developed for clinical detection of apoptosis in vivo by positron emission tomography (PET). [18F]-ML-10 is a member of the ApoSense family of compounds, a novel class of molecular probes for molecular imaging of cell death. The first clinical indication for which [18F]-ML-10 is being developed is imaging of apoptosis in clinical oncology to monitor tumor response to radiation therapy.
Previous preclinical and clinical studies have substantiated the safety of [18F]-ML-10, its very high stability in vivo, its favorable biodistribution profile, and its efficacy in clinical detection of cell death. In preclinical studies, the selective retention of [18F]-ML-10 in the focus of the neurovascular cell death in cerebral ischemia was demonstrated in respective animal models. 18F-ML-10 has been examined in two clinical trials in Uppsala Imanet, Sweden, and has been found safe in administration to healthy subjects and to elderly subjects with acute ischemic cerebral stroke. In these clinical trials, [18F]-ML-10 was also found efficacious in the clinical imaging of apoptosis, being either physiological apoptosis as observed in the testes in young healthy males, and pathological cell death, as observed in the brains of patients with acute ischemic cerebral stroke.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients with cancer, diagnosed as having brain metastases, wherein at least one of the tumors has the diameter of ≥ 1.5cm, as assessed by MRI or CT performed within 14 days prior to screening/enrollment.
- Patients scheduled for WBRT.
- Fully conscious patients who have been given written and verbal information, and have then provided informed consent.
Exclusion Criteria:
- Unstable medical condition, such as ischemic heart disease, liver disease or pulmonary disease, which may risk the patient during the study, as judged by the investigator.
- Renal failure, with serum creatinine > 1.5mg/dl.
- Any known psychiatric disorder other than mild depression or anxiety.
- Patients treated for diabetes mellitus either by oral hypoglycemic medications or insulin.
- Allergy to any known medication or to any imaging agent, or allergy-originated diseases, as judged by the investigator.
- Other condition that might jeopardize the safety of the patient or the evaluation of the study results, as judged by the investigator.
- Treatment with any non-marketed investigational drug within 30 days prior to administration of [18F]-ML-10.
- Current alcohol or drug abuse
- Pregnancy or lactation.
- Women of child-bearing potential who are not using an adequate and medically acceptable contraceptive method.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: 18F ML-10
Intervention - 18F ML-10 PET/CT imaging for early detection of response of brain metastases to WBRT
|
Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment.
Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Assessment of a change in the uptake of [18F]- ML-10 by the tumor as observed in comparing the PET scans before and after WBRT.
Lasso di tempo: 3 months
|
3 months
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Assessment of a relationship between the change in uptake of [18F]- ML-10 by the tumor, observed in the PET scans obtained during the study, and tumor shrinkage in response to treatment, as assessed by MRI or CT according to the RECIST criteria.
Lasso di tempo: 3 months
|
3 months
|
Detection of a potential change in the uptake of [18F]- ML-10 by the healthy brain tissue, as observed in comparing the PET/CT scans before and after WBRT, reflecting potential damage to intact brain tissue, as an adverse effect of the irradiation.
Lasso di tempo: 3 months
|
3 months
|
Assessment of the correlation between the PET/CT region of interest (ROI), delineated by [18F]-ML-10 imaging, and the corresponding anatomical imaging.
Lasso di tempo: 3 months
|
3 months
|
Assessment of the safety of [18F]-ML-10 when administered to cancer patients undergoing WBRT.
Lasso di tempo: one month
|
one month
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Aaron Allen, M.D., Rabin Medical Center, Petach Tikva 49100, Israel
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- NST-CA001CTIL
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Tumori solidi
-
AstraZenecaReclutamentoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, carcinoma gastrico, mammario e ovaricoSpagna, Stati Uniti, Belgio, Regno Unito, Francia, Ungheria, Canada, Corea, Repubblica di, Australia
Prove cliniche su 18F ML-10
-
Aposense Ltd.SconosciutoNeoplasie della testa e del collo | Carcinoma, polmone non a piccole celluleStati Uniti
-
Aposense Ltd.Sconosciuto
-
Novo Nordisk A/SCompletato
-
Ampio Pharmaceuticals. Inc.Completato
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityCompletatoSindrome da rilascio di citochine | Polmonite Covid-19Pakistan
-
Dr Cipto Mangunkusumo General HospitalAttivo, non reclutanteComplicazione della ventilazione meccanicaIndonesia
-
Alaa MazyCompletato
-
AmtixBio Co., Ltd.Novotech (Australia) Pty LimitedCompletato
-
Institut Claudius RegaudAttivo, non reclutanteCancro al seno triplo negativo senza coinvolgimento dei linfonodi e < o = 30 mmFrancia
-
Medical College of WisconsinNational Heart, Lung, and Blood Institute (NHLBI); University of California,... e altri collaboratoriCompletatoMalattia cardiovascolare | Fallimento e rigetto del trapianto di cuore | Rigetto del trapianto cardiaco | Rigetto acuto del trapianto cardiacoStati Uniti